EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 4 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Breast Cancer Survivor Given 12 Months to Live After Left Side... April 2, 2021 Study Shows Thymic Health is Linked to Cancer Patients’ Response to... October 16, 2025 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Closing the gap: How new screening interventions could reduce inequalities in... July 5, 2022 Load more HOT NEWS Bean there done that: Can swapping to pulses be the new... Cómo puede ayudar la terapia del piso pélvico a las personas... We have a Deal: What does the new UK-EU relationship mean... How Being an Athlete Prepared Me for My Cancer Experience
